Salignostics

Executive Summary

Salignostics is an Israeli med-tech company pioneering saliva-based rapid diagnostics. Its proprietary platform enables non-invasive detection of proteins, DNA, and RNA from saliva, offering a user-friendly alternative to traditional blood or nasal swab tests. The flagship product, Salistick™, is a CE-approved saliva pregnancy test available over-the-counter in Europe, addressing a significant market need for comfortable home testing. The company is expanding its platform into infectious disease diagnostics, developing tests for respiratory viruses, STIs, and other point-of-care applications. With a focus on decentralized testing, Salignostics is well-positioned in the rapid diagnostics sector. The company is pursuing FDA clearance for its pregnancy test in the U.S., a major market opportunity. Concurrently, it is advancing infectious disease assays, with potential CE marking and launch soon. The technology could transform diagnostics by reducing cost and improving access. However, competition and regulatory hurdles remain. Near-term catalysts include regulatory milestones and product launches, making Salignostics a promising but early-stage investment in non-invasive diagnostics.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for Salistick pregnancy test in U.S.60% success
• Q2 2026Launch of infectious disease test (e.g., Flu A/B+COVID) in Europe70% success
• Q3 2026Strategic partnership for distribution in Asia50% success